The Market Reports

Synopsis

The global market for Synthetic Biology Technology was estimated to be worth US$ 1736 million in 2024 and is forecast to a readjusted size of US$ 4447 million by 2031 with a CAGR of 14.0% during the forecast period 2025-2031.

Synthetic Biology Technology is an interdisciplinary engineering-driven platform that redesigns, constructs, and programs biological systems. It spans gene synthesis, genetic circuit design, metabolic engineering, the construction of cellular factories, and the integration of bioinformatics with automation. Using modular genetic parts, high-throughput DNA synthesis and sequencing, and machine-learning-guided design-build-test-learn (DBTL) cycles, synthetic biology transforms organisms into programmable “biological machines” for novel therapeutics, precision diagnostics, sustainable materials, and agricultural or energy solutions. As an upstream enabler of the biotech value chain, synthetic biology accelerates the shift from lab-scale experiments to commercial biological manufacturing, creating strategic differentiation and long-term enterprise value.

The strategic pursuit of sustainable alternatives, precision medicines, and biological manufacturing by industry and governments is accelerating the industrialization of synthetic biology. Corporate filings show that leading companies are positioning synthetic biology as a long-term growth driver, enhancing platform capabilities, automation, and partner ecosystems to increase delivery speed and product breadth; meanwhile, national engineering biology strategies and public research funding reduce commercialization uncertainty and channel capital and industry resources into the field. Technological advances—lowering costs in DNA synthesis and high-throughput screening and embedding AI and automation into the DBTL cycle—shorten the pathway from concept to scalable product, offering visible strategic value and profit potential to CEOs, marketers, and investors.Commercial deployment of synthetic biology faces regulatory, ethical, and biosafety challenges: inconsistent cross-border governance of biological data and samples, evolving gene-editing regulations, and the social sensitivity of high-risk biological work demand greater investments in compliance and transparency. Platform strategies also create technical and capital barriers, making scale-up and market entry difficult for smaller innovators. Moreover, scale-up uncertainties, environmental and ethical controversies, and systemic risks must be weighed by investors and boards when shaping strategic initiatives. End markets are shifting from single-point technology purchases toward platformized, customized services: pharma companies and CROs prefer deep partnerships with providers that offer end-to-end DBTL and scalable manufacturing to compress timelines to clinic; agriculture, materials, and energy sectors seek bio-manufactured alternatives to fossil feedstocks and favor platforms with proven scale-up performance. Concurrently, demand is rising for verifiable compliance, product traceability, and supply-chain resilience—advantages that integrated “technology + manufacturing + compliance” vendors can leverage to win large customers and long-term contracts.

This report aims to provide a comprehensive presentation of the global market for Synthetic Biology Technology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Synthetic Biology Technology by region & country, by Type, and by Application.

The Synthetic Biology Technology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Synthetic Biology Technology.

Market Segmentation

By Company

• Genescript
• Thermo Fisher Scientific
• IDT
• Eurofins Genomics
• DNA 2.0 (ATUM)
• BBI
• Azenta Life Sciences
• SBS Genetech
• Bio Basic
• Twist Bioscience
• OriGene
• Bioneer
• Eton Bioscience
• Synbio Technologies
• Eurogentec
• Ginkgo Bioworks
• Agilent

Segment by Type

• Gene Synthesis
• Oligonucleotide Synthesis
• Bioinformatics Analysis
• DNA Assembly

Segment by Application

• Medicine
• Chemical Industry
• Agriculture
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.